#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

March 16, 2026·53 min·3 clips

Attia's close friend had sky-high 'good' HDL cholesterol for 20 years — then a calcium scan revealed severe hidden heart disease.

Peter starts with the premise. This is not a normal interview episode; it is a focused explanation of Obicetrapib and why it has caught his attention. The mechanics do most of the work. The question is whether this class can lower ApoB and reduce cardiovascular risk without bringing back the off-target problems that hurt earlier drugs. The history is messy, which is why Peter spends time on it. Lilly becomes the first cautionary case: lifetime ApoB reduction may matter, but a short trial can still miss the benefit. Lilly pulled its drug in 2015. Peter then turns to Merck’s anacetrapib program. Added to atorvastatin, it produced about a 9% or 10% drop in coronary events over roughly four years. Useful, yes. Dramatic, no. With longer follow-up, the benefit reached about 12% over about six years, which Peter says fits the amount of ApoB lowering. The timing did the drug no favors. PCSK9 inhibitors were arriving at the same moment with much bigger metric changes, so anacetrapib looked restrained next to them. Even so, Peter treats REVEAL as proof that CETP inhibitors could lower ApoB particles and reduce cardiovascular events if the safety problems were avoided. Then the catch arrives. Anacetrapib had a very long half-life and stayed in fat cells. That was not shown to cause harm, but Peter thinks it likely influenced Merck’s decision. He labels that part as speculation and ties it to Merck’s experience with Vioxx, where safety memory may have made the company more cautious. The tone stays careful. The excitement comes from the possibility that newer drugs learned the right lessons from earlier failures. The episode closes with the usual education-only framing and points listeners to Peter’s public conflicts of interest disclosures.

As heard by us

A technical, cautious case for why obicetrapib has put CETP inhibitors back on Attia's radar.

Peter Attia gives obicetrapib a full episode, using the CETP inhibitor to revisit a drug class that has had a messy cardiovascular history. The strongest section is the trial walk-through: Lilly's program failing to show benefit, Merck's anacetrapib showing a modest reduction in…

Read the full review in PlayNext →

Why you'd press play

One drug, one solo hour, and a backstory of failed predecessors that makes this one actually matter.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from The Peter Attia Drive